Key result
Metformin treatment impairs the homing ability and efficacy of mesenchymal stem cell therapy for cardiac repair in rats with streptozotocin-induced diabetic cardiomyopathy.
Key points are not available for this paper at this time.
Population
Streptozotocin-induced diabetic cardiomyopathy in rats
Metformin may blunt MSC therapy benefits in diabetic cardiomyopathy; hypothesis-generating for clinical stem cell regimens.
Metformin treatment reduces the efficacy of mesenchymal stem cell therapy for cardiac repair during diabetic cardiomyopathy. Stem cell therapy in diabetics may be more effective in combination with AMPK inhibitors.
No takes yet. Share an insight, caveat, or question.
Ammar et al. (2021) studied this question. Metformin treatment impairs the homing ability and efficacy of mesenchymal stem cell therapy for cardiac repair in rats with streptozotocin-induced diabetic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: